Petter Bjornstad1,2, Pattara Wiromrat3, Richard J Johnson4, Rachel Sippl2, David Z I Cherney5, Randy Wong2, Marian J Rewers2, Janet K Snell-Bergeon2. 1. Section of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO petter.bjornstad@childrenscolorado.org. 2. Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO. 3. Section of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO. 4. Division of Renal Disease and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. 5. Division of Nephrology, Department of Medicine, and Department of Physiology, University of Toronto, Ontario, Canada.
Abstract
OBJECTIVE: Novel biomarkers are needed to better predict coronary artery calcification (CAC), a marker of subclinical atherosclerosis, and diabetic kidney disease (DKD) in type 1 diabetes. We evaluated the associations between serum uromodulin (SUMOD [a biomarker associated with anti-inflammatory and renal protective properties]), CAC progression, and DKD development over 12 years. RESEARCH DESIGN AND METHODS: Participants (n = 527, 53% females) in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study were examined during 2002-2004, at a mean age of 39.6 ± 9.0 years and a median duration of diabetes of 24.8 years. Urine albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) determined by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation were measured at baseline and after a mean follow-up period of 12.1 ± 1.5 years. Elevated albumin excretion was defined as ACR ≥30 mg/g, rapid GFR decline (>3 mL/min/1.73 m2/year), and impaired GFR as eGFR <60 mL/min/1.73 m2. SUMOD was measured on stored baseline plasma samples (Meso Scale Discovery). CAC was measured using electron beam computed tomography. CAC progression was defined as a change in the square root-transformed CAC volume of ≥2.5. RESULTS: Higher baseline SUMOD level conferred lower odds of CAC progression (odds ratio 0.68; 95% CI 0.48-0.97), incident elevated albumin excretion (0.37; 0.16-0.86), rapid GFR decline (0.56; 0.35-0.91), and impaired GFR (0.44; 0.24-0.83) per 1 SD increase in SUMOD (68.44 ng/mL) after adjustment for baseline age, sex, systolic blood pressure, LDL cholesterol, and albuminuria/GFR. The addition of SUMOD to models with traditional risk factors also significantly improved the prediction performance for CAC progression and incident DKD. CONCLUSIONS: Higher baseline SUMOD level predicted lower odds of both CAC progression and incident DKD over 12 years in adults with type 1 diabetes.
OBJECTIVE: Novel biomarkers are needed to better predict coronary artery calcification (CAC), a marker of subclinical atherosclerosis, and diabetic kidney disease (DKD) in type 1 diabetes. We evaluated the associations between serum uromodulin (SUMOD [a biomarker associated with anti-inflammatory and renal protective properties]), CAC progression, and DKD development over 12 years. RESEARCH DESIGN AND METHODS: Participants (n = 527, 53% females) in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study were examined during 2002-2004, at a mean age of 39.6 ± 9.0 years and a median duration of diabetes of 24.8 years. Urine albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) determined by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation were measured at baseline and after a mean follow-up period of 12.1 ± 1.5 years. Elevated albumin excretion was defined as ACR ≥30 mg/g, rapid GFR decline (>3 mL/min/1.73 m2/year), and impaired GFR as eGFR <60 mL/min/1.73 m2. SUMOD was measured on stored baseline plasma samples (Meso Scale Discovery). CAC was measured using electron beam computed tomography. CAC progression was defined as a change in the square root-transformed CAC volume of ≥2.5. RESULTS: Higher baseline SUMOD level conferred lower odds of CAC progression (odds ratio 0.68; 95% CI 0.48-0.97), incident elevated albumin excretion (0.37; 0.16-0.86), rapid GFR decline (0.56; 0.35-0.91), and impaired GFR (0.44; 0.24-0.83) per 1 SD increase in SUMOD (68.44 ng/mL) after adjustment for baseline age, sex, systolic blood pressure, LDL cholesterol, and albuminuria/GFR. The addition of SUMOD to models with traditional risk factors also significantly improved the prediction performance for CAC progression and incident DKD. CONCLUSIONS: Higher baseline SUMOD level predicted lower odds of both CAC progression and incident DKD over 12 years in adults with type 1 diabetes.
Authors: Marcus D Säemann; Thomas Weichhart; Maximilian Zeyda; Günther Staffler; Michael Schunn; Karl M Stuhlmeier; Yuri Sobanov; Thomas M Stulnig; Shizuo Akira; Alexander von Gabain; Uwe von Ahsen; Walter H Hörl; Gerhard J Zlabinger Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Andreas Leiherer; Axel Muendlein; Christoph H Saely; Eva M Brandtner; Kathrin Geiger; Peter Fraunberger; Heinz Drexel Journal: J Hypertens Date: 2018-01 Impact factor: 4.844
Authors: Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel Journal: Diabetes Care Date: 2014-08-11 Impact factor: 19.112
Authors: Roxana Djaberi; Joanne D Schuijf; Eric Boersma; Lucia J M Kroft; Alberto M Pereira; Johannes A Romijn; Arthur J Scholte; J Wouter Jukema; Jeroen J Bax Journal: Diabetes Care Date: 2009-06-01 Impact factor: 17.152
Authors: Dominik Steubl; Petra Buzkova; Pranav S Garimella; Joachim H Ix; Prasad Devarajan; Michael R Bennett; Paulo H M Chaves; Michael G Shlipak; Nisha Bansal; Mark J Sarnak Journal: Nephrol Dial Transplant Date: 2020-08-01 Impact factor: 5.992
Authors: Paul Perco; Wenjun Ju; Julia Kerschbaum; Johannes Leierer; Rajasree Menon; Catherine Zhu; Matthias Kretzler; Gert Mayer; Michael Rudnicki Journal: JCI Insight Date: 2019-06-20
Authors: Pattara Wiromrat; Petter Bjornstad; Carlos Roncal; Laura Pyle; Richard J Johnson; David Z Cherney; Tyler Lipina; Franziska Bishop; David M Maahs; R Paul Wadwa Journal: J Diabetes Complications Date: 2019-06-03 Impact factor: 2.852
Authors: Dominik Steubl; Markus P Schneider; Heike Meiselbach; Jennifer Nadal; Matthias C Schmid; Turgay Saritas; Vera Krane; Claudia Sommerer; Seema Baid-Agrawal; Jakob Voelkl; Fruzsina Kotsis; Anna Köttgen; Kai-Uwe Eckardt; Jürgen E Scherberich Journal: Clin J Am Soc Nephrol Date: 2020-04-14 Impact factor: 8.237
Authors: Vasantha Jotwani; Pranav S Garimella; Ronit Katz; Rakesh Malhotra; Jeffrey Bates; Alfred K Cheung; Michel Chonchol; Paul E Drawz; Barry I Freedman; William E Haley; Anthony A Killeen; Henry Punzi; Mark J Sarnak; Mark S Segal; Michael G Shlipak; Joachim H Ix Journal: Am J Nephrol Date: 2020-09-09 Impact factor: 3.754